 This Phase 3 study evaluated the safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine, 4C-MNB, co-administered with routine vaccines in Taiwanese infants. The study found that immune responses to all 4 antigens were sufficient at both primary and booster vaccination, and the immunogenicity of 4C-MNB was not impacted by co-administration with routine pediatric vaccines. Reactogenicity was slightly higher in the 4C-MNB plus routine group compared with the routine group, but no safety concerns were identified. This article was authored by Nanchang Chu, Li Minit Wang, Arnold Williamson, and others.